About C2 domain-containing protein 3
C2 domain-containing protein 3 (C2CD3) is a protein
from Homo sapiens identified by UniProt accession
Q4AC94, 2353 residues long.
MolForge cross-references it against 0 known binders and
46 disease associations.
Target properties
| Protein name | C2 domain-containing protein 3 |
| UniProt accession | Q4AC94 |
| Gene | C2CD3 |
| Organism | Homo sapiens |
| Length | 2353 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (46)
Diseases linked to this target (Open Targets).
- orofaciodigital syndrome type 14 · score 0.78
- orofaciodigital syndrome · score 0.52
- Orofaciodigital syndrome type 1 · score 0.50
- Short rib-polydactyly syndrome, Verma-Naumoff type · score 0.50
- asphyxiating thoracic dystrophy 3 · score 0.50
- orofaciodigital syndrome I · score 0.50
- Joubert syndrome · score 0.46
- genetic disorder · score 0.19
- Jeune syndrome · score 0.15
- blood protein measurement · score 0.15
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q4AC94-F1 | alphafold | PREDICTED | 55.05 | — |
Amino-acid sequence (2353 residues)
MKQRKGQGSG GSRGRKKRGL SDISPSTSLP PLVEGQLRCF LKLTVNRVIW KIAKPPTCVL VRVRWWGETS DGTLFCPRDA LQTEPKAVRT TTRYAIRCGP KQFTSYLTDM AVLVLEVITK LDGLPIGRVQ INGLAQLSPT HQINGFFTIV SSTSKKLGEL QVSLALEPLS ETYDSYHPLP TTDMTENVLL SKQGFRENTE PSSTQFQVPS RPRDIHTIKI DGKELAANSS RSTTPRGKDH VCFAENPDTI KDSSFGLQHS LNSGQSLESV TLKGRAPRKQ MSLLNSSEFQ PQIRTVAKSH SDSCILSSNN LPTKDLLSAL LEQGNKLRNA MVISAMKSSP ETSMLLDQVH PPINEDSLRA STQIRAFSRN RFKDHIEDHL LPSTENTFWR HDTKADTRAI QLLLGSAELS QGNFWDGLGS PPDSPSPGSD VYCISELNDP QYDQSLLENL FYTAPKSDTS ISDFLSEEDD IVPSKKISQS TALARSSKVL ESSDHKLKKR SAGKRNRNLV EQQMLSETPE DAQTMTLSVD RLALLGRTHS VRIIIETMGV PPDSPQMTPG KKSYAGPPPK VTTAKKRTFF VEYHFPVGFS ESGLGKTALI TEVVRLASSK ITDGKVKFQQ RFVFPVQFGG PMIEHWWNSN LTFQIYVKKT PQKKPEVIGS VSLSLRAVIQ SELLSFSDQL PVQQENGQSP FGPLKVTMEL ITDNKDFTGI NTKLSGNTHY TPLCAPTSPN KALPELNQDM TCTKNPQNLN QIHEETAKKA QNLVLPNRKS PSPVAPHPST FVATPASHNL VNQTNGTTKE SALLLHVLLM VPDGKDFISG ESEKQSPCNV YLNCKLFSTE EVTRSVIAWG TTQPVFNFSQ VIPVSLSSKY LERLKNNVMV IETWNKVRSP GQDKLLGLVK LPLHQFYMSF KDAKISRLLL DAQYPVVAVD SYMPVIDVFS GHQNGSLRVF LAMGSSNQIM ALQRLKNEEG TLPPFSPRPA HFLDQPTAAS VAMAEDRGNG LMEHCFEIHI EMVKGLAPLQ ATVWGEADCY VQYYFPVQHS QSSVLKGPEF LENGITLKPF RTATTLCVPD PIFNSEHHHS LLLPAEVPVQ RLLLSAFSAQ GLVPGGGVQF EIWCRYYYPN VRDQKVAKGT LPLSRICAMV TTQHREDVGI QTFNLPLTPR IENRKELRNQ SSGLLDVGLR YRRSPRTAEG VLAARTVSIS VQIIRACGLQ AAAKALAERE PALQFSATVG VNASVTTHLS FLPQGEQRRT HPVACSFCPE FSHHVEFTCN LVTQHCSGEA CFLAELLEFA EVIFAVYHEN TKSASDIISI ESCKEYLLGV VKVPTKELLI KRSGITGWYP IILPEDGGLP HGLELMQKIV GGLELSISFT HRGDRERVLE AAEHLGWSFE NSLKDFVRMD EGEPATVTIS TPRLWLPIHC VLLAGHNHIH KNTYCYLRYK FYDHEAFWTP LKKPKESVNK KQIMVTFKAS KRAEVTRGPS LLWYFREERL EIQVWRAYGN DSVERPHQTD SWIGSAYVDL ARLGERSART LTVSGVYPLF GRNASNLSGA ALRVHVVLSS LSSHLEPTHE LDSMDCSSHS ESEQLPRRND EVQLSPPEVI SCHQKSPAST QVPCSSTTAE VRLTQEGPAD LDGTFAVSIL VERAMHLSLK GSPLTERKVS IPSCCVSFAT ADESSPVYTQ VVENTDSPIW NFQQQSRLSK ELLLDPQQTL VFKVWHKGDE ERVIGFASVD LSPLLSGFQF VCGWYNITDF SGECQGQIKV AVSPLESLIH FKEERQARRG VETSKSLIPI YSPFSFPASD TYAAFSSHMA RQTLDQLAHA SSKELDFSSP GRSDTTRSQA SRHEEHVQNI RRFHESLHLQ GEAPLPCDDK LTTSPLSSQT SILTSLRKNL SELDQIQRYF RQKLTKPFLP LSPQTQTAIS QHQESCRDHL GPGASSLDPG SQCILEKSSN LVLQVSSLIT DLQTITRDSQ AALSSHRARS RSNKATTLPD AQDTEALQER CTMPDEPLVR APDKGTDSPS PPPLEETSNG GRMLHESLRH AVPITRMQSS EDTEAGPAYS DEDYEEDIIE PRTLNEITTV TDKTSPWSSV ISDTSEVISP QPDEVQREGP SCPSPGPFCR EELMVKSSFL SSPERAVNPH LPRQGSPSQS LVACECEASK ARVGGESASA NPQPIPCPTL SGAQQSSTFV GWSSPQTDQN KEPKSEAPAE NEAATSELGD SADSFKKLPL NLASQSRREN HKGPPIDSSD IRQRQVTTGS ETSTKQSLLL PGPIVVPNFF LPPQQLEASL RMLSLSATLP PAATTDQDKS EATRGALSQR PCRPRPNSLP LNLPEEETLR IARIFSSQYS QKD
Explore C2 domain-containing protein 3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets